From August through November 2007 The patient received doxorubicin and ifosfamide, accompanied by maintenance therapy with imatinib until February 2008, when follow-up CT revealed asymptomatic, multifocal, recurrent peritoneal nodules. After meeting eligibility requirements and providing written educated consent, the individual began receiving crizotinib on March 25, 2008, at a dosage of 200 mg daily twice. On May 21, 2008, and June 19, 2008, CT scanning demonstrated reductions of 40 percent and 53 percent, respectively, in the sum of unidimensional measurements of focus on lesions, which was classified as a partial response, based on the Response Evaluation Requirements in Solid Tumors 17 .We used the chi-square test to compare the patients’ sputum-culture position at the end of eight weeks across treatment organizations and the log-rank test to compare the time to culture-negative status. We used similar methods to analyze other secondary outcomes, including the time to an unfavorable outcome, the status at the ultimate end of treatment, the status at 12 and 18 months among sufferers with a favorable outcome at end of treatment, and the position at 18 months relating to a blinded scientific overview of the data. All sufferers who received at least 1 dosage of a scholarly research medication were contained in the safety analysis.